Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecentriq Hybreza
atezolizumab + hyaluronidase-tqjs · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Expands subcutaneous use in unresectable or metastatic alveolar soft part sarcoma to pediatric patients age 12 years or older who weigh at least 40 kg.
LAMPGEN ANALYSIS
Why it matters
The subcutaneous formulation became an option for eligible adolescents with this rare sarcoma.
What research teams should watch
Confirm age and weight and coordinate specialty sarcoma assessment with route-specific administration training.
PRIMARY RECORDS